251 related articles for article (PubMed ID: 21824055)
1. Bringing greater transparency to "black box" warnings.
Buckley NA; Rossi S
Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
[TBL] [Abstract][Full Text] [Related]
2. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
Matlock A; Allan N; Wills B; Kang C; Leikin JB
Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
[TBL] [Abstract][Full Text] [Related]
3. FDA boxed warnings: how to prescribe drugs safely.
O'Connor NR
Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
[TBL] [Abstract][Full Text] [Related]
4. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
Murphy S; Roberts R
J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
[TBL] [Abstract][Full Text] [Related]
5. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs.
Wang LM; Wong M; Lightwood JM; Cheng CM
Ann Pharmacother; 2010 Jan; 44(1):28-34. PubMed ID: 20040698
[TBL] [Abstract][Full Text] [Related]
6. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Yeh JS; Sarpatwari A; Kesselheim AS
Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
[TBL] [Abstract][Full Text] [Related]
7. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
[TBL] [Abstract][Full Text] [Related]
8. Boxed warning inconsistencies between drug information resources and the prescribing information.
Cheng CM; Fu C; Guglielmo BJ; Auerbach AD
Am J Health Syst Pharm; 2011 Sep; 68(17):1626-31. PubMed ID: 21856808
[TBL] [Abstract][Full Text] [Related]
9. Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development.
Nieminen O; Kurki P; Nordström K
Eur J Pharm Biopharm; 2005 Aug; 60(3):319-26. PubMed ID: 15996576
[TBL] [Abstract][Full Text] [Related]
10. The impact of wording in "Dear doctor" letters and in black box labels.
Weatherby LB; Nordstrom BL; Fife D; Walker AM
Clin Pharmacol Ther; 2002 Dec; 72(6):735-42. PubMed ID: 12496755
[TBL] [Abstract][Full Text] [Related]
11. Prescriber compliance with black box warnings in older adult patients.
Ricci JR; Coulen C; Berger JE; Moore MC; McQueen A; Jan SA
Am J Manag Care; 2009 Nov; 15(11):e103-8. PubMed ID: 19895180
[TBL] [Abstract][Full Text] [Related]
12. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.
Kesselheim AS; Franklin JM; Avorn J; Duke JD
BMJ Qual Saf; 2013 Sep; 22(9):727-34. PubMed ID: 23620531
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
14. The Value of the Black Box Warning in Dermatology.
Winterfield L; Vleugels RA; Park KK
J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
[TBL] [Abstract][Full Text] [Related]
15. Adherence to black box warnings for prescription medications in outpatients.
Lasser KE; Seger DL; Yu DT; Karson AS; Fiskio JM; Seger AC; Shah NR; Gandhi TK; Rothschild JM; Bates DW
Arch Intern Med; 2006 Feb; 166(3):338-44. PubMed ID: 16476875
[TBL] [Abstract][Full Text] [Related]
16. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
[TBL] [Abstract][Full Text] [Related]
17. FDA drug prescribing warnings: is the black box half empty or half full?
Wagner AK; Chan KA; Dashevsky I; Raebel MA; Andrade SE; Lafata JE; Davis RL; Gurwitz JH; Soumerai SB; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):369-86. PubMed ID: 16294363
[TBL] [Abstract][Full Text] [Related]
18. Black box warnings: what do they mean to pharmacists and patients.
Martin CM; Borgelt L
Consult Pharm; 2012 Jul; 27(7):482-92. PubMed ID: 22910129
[TBL] [Abstract][Full Text] [Related]
19. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
Cook DM; Gurugubelli RK; Bero LA
Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
